The Europe Companion Animal Arthritis Market would witness market growth of 5.9% CAGR during the forecast period (2022-2028). There are several symptoms that can help in the identification of arthritis in companion animals including an unwillingness to move, trailing behind on walks, having a limp, discomfort or stiffness upon rising or falling, when touched, yowling A personality shift (aggression when normally good-natured), an urge to lick the injured joints. As arthritis gets worse and the symptoms develop, they become more evident. Dog arthritis cannot be healed because of the alterations that have taken place in the affected joint or joints. However, the discomfort and agony can be properly treated and controlled. Making an appointment with the veterinarian for a comprehensive clinical evaluation is the first step in controlling arthritis. General anesthesia and radiographs are typically needed to accurately diagnose the animal's health and to pinpoint the precise problem in the animal's joints. Then, a multifaceted strategy might be developed for their particular scenario. Large and large breed dogs, such as Labrador retrievers or German Shepherds, may be genetically predisposed to developing hip and elbow joint illness. The adoption of pets is surging in this region at a very rapid pace. In 2020, as per the European Pet Food Industry, 88 million households in this region had one or more pets, including 110 million cats, 90 million dogs, and 52 million other pets. There is a significant risk as well as a prevalence of animal arthritis in the region. Moreover, the healthcare infrastructure of Europe is very robust, which would allow regional market players to introduce a number of novel medicines and advanced approaches to cure arthritis in animals. The Germany market dominated the Europe Companion Animal Arthritis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $249.7 million by 2028. The UK market is anticipated to grow a CAGR of 5% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 6.7% during (2022 - 2028). Based on Indication, the market is segmented into Osteoarthritis and Other Arthritis. Based on Distribution Channel, the market is segmented into Veterinary Hospitals & Clinics, Retail Pharmacies, Online Stores and Others. Based on Treatment, the market is segmented into Medication, Supplements and Other Treatment. Based on Animal Type, the market is segmented into Dogs, Cats and Other. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Dechra Pharmaceuticals PLC, Elanco Animal Health, Inc., Zoetis, Inc., Vetoquinol SA, Virbac, Ceva Sant? Animale, Eltech K-Laser s.r.l., Norbrook Laboratories Limited, and NexGen Pharmaceuticals, LLC. Scope of the Study Market Segments covered in the Report: By Indication ? Osteoarthritis ? Other Arthritis By Distribution Channel ? Veterinary Hospitals & Clinics ? Retail Pharmacies ? Online Stores ? Others By Treatment ? Medication ? Supplements ? Other Treatment By Animal Type ? Dogs ? Cats ? Others By Country ? Germany ? UK ? France ? Russia ? Spain ? Italy ? Rest of Europe Companies Profiled ? Boehringer Ingelheim International GmbH ? Dechra Pharmaceuticals PLC ? Elanco Animal Health, Inc. ? Zoetis, Inc. ? Vetoquinol SA ? Virbac ? Ceva Sant? Animale ? Eltech K-Laser s.r.l. ? Norbrook Laboratories Limited ? NexGen Pharmaceuticals, LLC Unique Offerings from KBV Research ? Exhaustive coverage ? Highest number of market tables and figures ? Subscription based model available ? Guaranteed best price ? Assured post sales research support with 10% customization free